Development costs for new therapeutics are rising on a continuous basis due to increasingly complex internal and external factors. I believe that it is of critical importance to invest an adequate effort in the starting phase of each pharmaceutical development. Making the best decision from a comprehensive pool of possible decisions defines the grade of innovation and thus the efficacy of the subsequent steps along the R&D pipeline.
"True innovation does not need primary cost optimization"
Professional experience: Companies and institutions
Max-Planck Institute for Molecular Genetics
The Scripps Research Institute
Robert Koch Institute
Bayer-Schering Pharma AG
Cellular Physiology and Biochemistry
OncoTargets and Therapy
International Journal of Oncology
Drug Design, Development and Therapy
International Journal of Nanomedicine